193 related articles for article (PubMed ID: 24730540)
1. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
5. A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Xu G; Wang B; Yang M; Qian W
Int J Clin Exp Pathol; 2015; 8(11):15025-9. PubMed ID: 26823839
[TBL] [Abstract][Full Text] [Related]
6. Potential new risks of lenalidomide.
Gertz MA; Buadi FK
Leuk Lymphoma; 2014 Sep; 55(9):1962-3. PubMed ID: 24304420
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with thalidomide and lenalidomide in multiple myeloma.
Moehler T
Curr Cancer Drug Targets; 2012 May; 12(4):372-90. PubMed ID: 22229246
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Monaghan SA; Dai L; Mapara MY; Normolle DP; Gollin SM; Lentzsch S
Leuk Lymphoma; 2013 Sep; 54(9):1965-74. PubMed ID: 23216269
[TBL] [Abstract][Full Text] [Related]
10. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Kuroda J; Kobayashi T; Taniwaki M
Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
[TBL] [Abstract][Full Text] [Related]
11. Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma.
Kiesewetter B; Raderer M
Leuk Lymphoma; 2015 Feb; 56(2):548-9. PubMed ID: 25120052
[No Abstract] [Full Text] [Related]
12. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
13. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Nozzoli C; Staderini M; Veltroni A; Longo G; Bacchiarri F; Donnini I; Guarrera A; Bosi A
Leuk Lymphoma; 2015; 56(8):2388-91. PubMed ID: 25535816
[TBL] [Abstract][Full Text] [Related]
14. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
15. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
[TBL] [Abstract][Full Text] [Related]
16. Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma: author's reply.
Montefusco V
Leuk Lymphoma; 2015 Feb; 56(2):550. PubMed ID: 25110822
[No Abstract] [Full Text] [Related]
17. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
[TBL] [Abstract][Full Text] [Related]
18. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
19. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
20. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
